Photo from investor.agenusbio.com
Jun 28, 2024, 13:09
Vittorio Studiale: Impressive pathological response rate with neoadjuvant BOT/BAL in MSS CRC
Vittorio Studiale, Medical Oncology Resident at University Hospital of Pisa, shared on X:
“Impressive pathological response rate (71%, pCR 35%) with neoadjuvant BOT/BAL in MSS colorectal cancer from the update of NEST-1 trial.”
Source: Vittorio Studiale/X
Agenus
Balstilimab
BOT/BAL
BOT/BAL immunotherapy
botensilimab
cancer
colorectal cancer
ESMO
ESMOGI24
European Society for Medical Oncology
Garo Armen
Jennifer Buell
Mehraneh Jafari
metastatic MSS colorectal cancer
MSS CRC
neoadjuvant BOT/BAL
NEST-1 trial
OncoDaily
Oncology
Pashtoon Kasi
Steven O'Day
Vittorio Studiale
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 17, 2024, 18:42
Sep 17, 2024, 18:36
Sep 17, 2024, 18:18
Sep 17, 2024, 17:05
Sep 17, 2024, 16:48
Sep 17, 2024, 16:42
Sep 17, 2024, 16:40
Sep 17, 2024, 16:34
Sep 17, 2024, 16:30